Podcasts about california san diego

The Open Society as an Enemy: A critique of how free societies turned against themselves by J. McKenzie Alexander Nearly 80 years ago, Karl Popper gave a spirited philosophical defence of the Open Society in his two-volume work, The Open Society and Its Enemies. In this book, J. McKenzie Alexander argues that a new defence is urgently needed because, in the decades since the end of the Cold War, many of the values of the Open Society have come under threat once again. Populist agendas on both the left and right threaten to undermine fundamental principles that underpin liberal democracies, so that what were previously seen as virtues of the Open Society are now, by many people, seen as vices, dangers, or threats. The Open Society as an Enemy: A Critique of how Free Societies Turned Against Themselves interrogates four interconnected aspects of the Open Society: cosmopolitanism, transparency, the free exchange of ideas, and communitarianism. Each of these is analysed in depth, drawing out the implications for contemporary social questions such as the free movement of people, the erosion of privacy, no-platforming and the increased political and social polarisation that is fuelled by social media. In re-examining the consequences for all of us of these attacks on free societies, Alexander calls for resistance to the forces of reaction. But he also calls for the concept of the Open Society to be rehabilitated and advanced. In doing this, he argues, there is an opportunity to re-think the kind of society we want to create, and to ensure it is achievable and sustainable. This forensic defence of the core principles of the Open Society is an essential read for anyone wishing to understand some of the powerful social currents that have engulfed public debates in recent years, and what to do about them. The book is publicly available via the following link The Open Society as an Enemy | LSE Press J. McKenzie Alexander is a Professor in Philosophy at the Department of Philosophy, Logic and Scientific Method in the London School of Economics. From 2012 to 2018, Professor Alexander served as one of the Academic Governors on the Council of the LSE, as well as a member of the Court of Governors. From 2018–2021, he served as the Head of Department. Before joining the department, Alexander was a Visiting Assistant Professor at the Department of Philosophy, University of California – San Diego (between 2000 and 2001). Although J. McKenzie Alexander's original field of research concerned evolutionary game theory as applied to the evolution of morality and social norms, more recently he has worked on problems in decision theory, more broadly construed, including topics in formal epistemology. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube Channel: https://www.youtube.com/user/a48266/videos Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/critical-theory

The Open Society as an Enemy: A critique of how free societies turned against themselves by J. McKenzie Alexander Nearly 80 years ago, Karl Popper gave a spirited philosophical defence of the Open Society in his two-volume work, The Open Society and Its Enemies. In this book, J. McKenzie Alexander argues that a new defence is urgently needed because, in the decades since the end of the Cold War, many of the values of the Open Society have come under threat once again. Populist agendas on both the left and right threaten to undermine fundamental principles that underpin liberal democracies, so that what were previously seen as virtues of the Open Society are now, by many people, seen as vices, dangers, or threats. The Open Society as an Enemy: A Critique of how Free Societies Turned Against Themselves interrogates four interconnected aspects of the Open Society: cosmopolitanism, transparency, the free exchange of ideas, and communitarianism. Each of these is analysed in depth, drawing out the implications for contemporary social questions such as the free movement of people, the erosion of privacy, no-platforming and the increased political and social polarisation that is fuelled by social media. In re-examining the consequences for all of us of these attacks on free societies, Alexander calls for resistance to the forces of reaction. But he also calls for the concept of the Open Society to be rehabilitated and advanced. In doing this, he argues, there is an opportunity to re-think the kind of society we want to create, and to ensure it is achievable and sustainable. This forensic defence of the core principles of the Open Society is an essential read for anyone wishing to understand some of the powerful social currents that have engulfed public debates in recent years, and what to do about them. The book is publicly available via the following link The Open Society as an Enemy | LSE Press J. McKenzie Alexander is a Professor in Philosophy at the Department of Philosophy, Logic and Scientific Method in the London School of Economics. From 2012 to 2018, Professor Alexander served as one of the Academic Governors on the Council of the LSE, as well as a member of the Court of Governors. From 2018–2021, he served as the Head of Department. Before joining the department, Alexander was a Visiting Assistant Professor at the Department of Philosophy, University of California – San Diego (between 2000 and 2001). Although J. McKenzie Alexander's original field of research concerned evolutionary game theory as applied to the evolution of morality and social norms, more recently he has worked on problems in decision theory, more broadly construed, including topics in formal epistemology. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube Channel: https://www.youtube.com/user/a48266/videos Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/intellectual-history

In Transformismo, M. Myrta Leslie Santana draws on years of embedded research within Cuban trans/queer communities to analyze how transformistas, or drag performers, understand their roles in the social transformation of the island. Once banned and censored in Cuba, transformismo, or drag performance, is now state-sponsored events. Transformismo suggests that these performances are making critical interventions in Cuban trans/queer life and politics and in doing so, the volume offers critical insight into how Cuba's postsocialist reform has exacerbated racial, sexual, and economic inequalities. Leslie Santana argues that mainstream trans/queer nightlife in Cuba is entangled with the island's tourism economy, which has shaped the aesthetics and social makeup of transformismo in coastal Havana, which largely caters to foreigners. Leslie Santana considers how Black lesbian and transgender transformistas are expanding understandings of sexual selfhood and politics on the island, particularly questioning the ways that Black women's creativity is prominently featured in the aesthetics of tourism and trans/queer nightlife, while Black women themselves are denied social and material capital. M. Myrta Leslie Santana is Assistant Professor of Music at the University of California San Diego. Katie Coldiron is the Outreach Program Manager for the Digital Library of the Caribbean (dLOC) and PhD student in History at Florida International University. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/gender-studies

Artificial intelligence is changing who can be a computer programmer. Leo Porter, professor of computer science and engineering at the University of California San Diego, explores how. Leo Porter is a Professor of Computer Science and Engineering at UC San Diego interested in computer science education research and computer architecture. Leo co-founded the Computing Education […]

In Transformismo, M. Myrta Leslie Santana draws on years of embedded research within Cuban trans/queer communities to analyze how transformistas, or drag performers, understand their roles in the social transformation of the island. Once banned and censored in Cuba, transformismo, or drag performance, is now state-sponsored events. Transformismo suggests that these performances are making critical interventions in Cuban trans/queer life and politics and in doing so, the volume offers critical insight into how Cuba's postsocialist reform has exacerbated racial, sexual, and economic inequalities. Leslie Santana argues that mainstream trans/queer nightlife in Cuba is entangled with the island's tourism economy, which has shaped the aesthetics and social makeup of transformismo in coastal Havana, which largely caters to foreigners. Leslie Santana considers how Black lesbian and transgender transformistas are expanding understandings of sexual selfhood and politics on the island, particularly questioning the ways that Black women's creativity is prominently featured in the aesthetics of tourism and trans/queer nightlife, while Black women themselves are denied social and material capital. M. Myrta Leslie Santana is Assistant Professor of Music at the University of California San Diego. Katie Coldiron is the Outreach Program Manager for the Digital Library of the Caribbean (dLOC) and PhD student in History at Florida International University. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/lgbtq-studies

In Transformismo, M. Myrta Leslie Santana draws on years of embedded research within Cuban trans/queer communities to analyze how transformistas, or drag performers, understand their roles in the social transformation of the island. Once banned and censored in Cuba, transformismo, or drag performance, is now state-sponsored events. Transformismo suggests that these performances are making critical interventions in Cuban trans/queer life and politics and in doing so, the volume offers critical insight into how Cuba's postsocialist reform has exacerbated racial, sexual, and economic inequalities. Leslie Santana argues that mainstream trans/queer nightlife in Cuba is entangled with the island's tourism economy, which has shaped the aesthetics and social makeup of transformismo in coastal Havana, which largely caters to foreigners. Leslie Santana considers how Black lesbian and transgender transformistas are expanding understandings of sexual selfhood and politics on the island, particularly questioning the ways that Black women's creativity is prominently featured in the aesthetics of tourism and trans/queer nightlife, while Black women themselves are denied social and material capital. M. Myrta Leslie Santana is Assistant Professor of Music at the University of California San Diego. Katie Coldiron is the Outreach Program Manager for the Digital Library of the Caribbean (dLOC) and PhD student in History at Florida International University. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

In Transformismo, M. Myrta Leslie Santana draws on years of embedded research within Cuban trans/queer communities to analyze how transformistas, or drag performers, understand their roles in the social transformation of the island. Once banned and censored in Cuba, transformismo, or drag performance, is now state-sponsored events. Transformismo suggests that these performances are making critical interventions in Cuban trans/queer life and politics and in doing so, the volume offers critical insight into how Cuba's postsocialist reform has exacerbated racial, sexual, and economic inequalities. Leslie Santana argues that mainstream trans/queer nightlife in Cuba is entangled with the island's tourism economy, which has shaped the aesthetics and social makeup of transformismo in coastal Havana, which largely caters to foreigners. Leslie Santana considers how Black lesbian and transgender transformistas are expanding understandings of sexual selfhood and politics on the island, particularly questioning the ways that Black women's creativity is prominently featured in the aesthetics of tourism and trans/queer nightlife, while Black women themselves are denied social and material capital. M. Myrta Leslie Santana is Assistant Professor of Music at the University of California San Diego. Katie Coldiron is the Outreach Program Manager for the Digital Library of the Caribbean (dLOC) and PhD student in History at Florida International University. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/latin-american-studies

In Transformismo, M. Myrta Leslie Santana draws on years of embedded research within Cuban trans/queer communities to analyze how transformistas, or drag performers, understand their roles in the social transformation of the island. Once banned and censored in Cuba, transformismo, or drag performance, is now state-sponsored events. Transformismo suggests that these performances are making critical interventions in Cuban trans/queer life and politics and in doing so, the volume offers critical insight into how Cuba's postsocialist reform has exacerbated racial, sexual, and economic inequalities. Leslie Santana argues that mainstream trans/queer nightlife in Cuba is entangled with the island's tourism economy, which has shaped the aesthetics and social makeup of transformismo in coastal Havana, which largely caters to foreigners. Leslie Santana considers how Black lesbian and transgender transformistas are expanding understandings of sexual selfhood and politics on the island, particularly questioning the ways that Black women's creativity is prominently featured in the aesthetics of tourism and trans/queer nightlife, while Black women themselves are denied social and material capital. M. Myrta Leslie Santana is Assistant Professor of Music at the University of California San Diego. Katie Coldiron is the Outreach Program Manager for the Digital Library of the Caribbean (dLOC) and PhD student in History at Florida International University. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/caribbean-studies

In Transformismo, M. Myrta Leslie Santana draws on years of embedded research within Cuban trans/queer communities to analyze how transformistas, or drag performers, understand their roles in the social transformation of the island. Once banned and censored in Cuba, transformismo, or drag performance, is now state-sponsored events. Transformismo suggests that these performances are making critical interventions in Cuban trans/queer life and politics and in doing so, the volume offers critical insight into how Cuba's postsocialist reform has exacerbated racial, sexual, and economic inequalities. Leslie Santana argues that mainstream trans/queer nightlife in Cuba is entangled with the island's tourism economy, which has shaped the aesthetics and social makeup of transformismo in coastal Havana, which largely caters to foreigners. Leslie Santana considers how Black lesbian and transgender transformistas are expanding understandings of sexual selfhood and politics on the island, particularly questioning the ways that Black women's creativity is prominently featured in the aesthetics of tourism and trans/queer nightlife, while Black women themselves are denied social and material capital. M. Myrta Leslie Santana is Assistant Professor of Music at the University of California San Diego. Katie Coldiron is the Outreach Program Manager for the Digital Library of the Caribbean (dLOC) and PhD student in History at Florida International University. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/performing-arts

In Transformismo, M. Myrta Leslie Santana draws on years of embedded research within Cuban trans/queer communities to analyze how transformistas, or drag performers, understand their roles in the social transformation of the island. Once banned and censored in Cuba, transformismo, or drag performance, is now state-sponsored events. Transformismo suggests that these performances are making critical interventions in Cuban trans/queer life and politics and in doing so, the volume offers critical insight into how Cuba's postsocialist reform has exacerbated racial, sexual, and economic inequalities. Leslie Santana argues that mainstream trans/queer nightlife in Cuba is entangled with the island's tourism economy, which has shaped the aesthetics and social makeup of transformismo in coastal Havana, which largely caters to foreigners. Leslie Santana considers how Black lesbian and transgender transformistas are expanding understandings of sexual selfhood and politics on the island, particularly questioning the ways that Black women's creativity is prominently featured in the aesthetics of tourism and trans/queer nightlife, while Black women themselves are denied social and material capital. M. Myrta Leslie Santana is Assistant Professor of Music at the University of California San Diego. Katie Coldiron is the Outreach Program Manager for the Digital Library of the Caribbean (dLOC) and PhD student in History at Florida International University. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/anthropology

Send us a textLaura Christine Sainz is the CEO & Founder of Live Vegan Vibrantly (www.liveveganvibrantly.com, live.began.vibrantly on Insta), a transformational and healthy lifestyle coaching company that provides integrative medicinal practices and holistic services to teach, train, educate, and empower individuals to successfully thrive a healthy whole-food, plant-based lifestyle while living meaningful, passionate lives. In this episode of THE SOULFAM PODCAST,  Laura shares with Diana her long history of healing with food, consciousness and a deep understanding of her own body. Laura holds a Certificate in Excellent Customer Service, is Certified in High Performance Coaching, a Certified Level II Reiki Practitioner, Certified Bikram Yoga Teacher, an Enagic Distributor, holds a Bachelor's of Arts in Psychology and Spanish Literature from Arizona State University, and a trained Integrative Medicinal Cooking Instructor from the University of California San Diego. Laura managed her first real health crisis, Chrohn's Disease,  chronic inflammatory bowel disease, with food as her ally. Bedridden for almost two years, Laura struggled against the medical establishment's recommendations and soldiered onward with only her own intuition and deft ability as a researcher. She transformed not only her body but enriched her soul and mental and emotional welll-being through her understanding of food. As a master health and transformational lifestyle expert, world traveler, and educator, Laura works with top leaders in her field, inspiring individuals to take their lives to the next level to heal their bodies naturally to achieve optimal health and healing, while living the life of their dreams. Her unique approach combines mindset, emotional intelligence and psychology training, integrative medicinal practices, macrobiotics, whole-food, plant-based nutrition, raw cuisine, yoga, breathwork, self love and many more holistic healing practices depending on clients' needs. Laura also strong opinions and experiences relating to the medical field. Having recently watched her father pass in a less than ideal environment and dealing with her own medical and physical issues, Laura feels the US's current medical system fails society on many deep levels. Laura feels chronic diseases such as diabetes, Alzheimer's Disease and more can be addressed through our food sytem not our medical system. In this interview, AI -- whose notice on food packaging has become more common recently --  is also discussed with regard to its growing influence on bioengineered food.  In this interview, Laura does not hesitate to share her opinions, research and deep experiences. If this resonates with you, please share your comments, ideas and experiences. You can also contact Laura at her website, www.liveveganvibrantly.com and subscribe to her deeply researched newsletter which shares a wealth of health and food-related information monthly. Laura also works with groups, teaches online and is available for individual consultation. Laura's free monthly newsletter can be subscribed to on www.liveveganvibrantly.com . Please remember to like and subscribe on THE SOULFAM PODCAST with Diana. Grateful for every like, share and comment. It helps the podcast grow and for the voices of souls such as Laura be heard. THANKS!!! Support the show@dianamarcketta@lexisaldin

I am so excited to say that my guest on the GWA Podcast is the esteemed American artist, Lorna Simpson. Working across photography to painting, video to collage, Simpson is a multimedia artist who – since the 1980s – has gained widespread acclaim for her pioneering approach to conceptual photography. Whether it's fusing text with image, obscuring her subject's identity, using techniques such as repetition, collage or manipulation – Simpson has conjured a plethora of ways to reinvent the image, and, by doing so, raises questions about gender, race, memory, and history. Her work, mostly centred on the female body, is full of seemingly open-ended narratives – as she has said: “I think the idea of identity or persona is interesting to me in that it is malleable and fluid. And that has always been part of the work in terms of [thinking about] who gets to determine who we are. Do we get to determine that, and what are the parameters of that, given the society that we live in?” Engaging with found images and objects, whether that be cut-outs from Ebony or Jet Magazines, or photographs she finds on eBay, which she melds with inks or collages of jewels, Simpson has continuously reconfigured what painting and photography means. Born in 1960, and raised in Queens and Brooklyn in a childhood that put the arts first, Simpson received her BFA from the School of Visual Arts, New York, and following that, an MFA from the University of California San Diego, where she began to focus on the portraits of Black women she found in magazines, adding suggestive phrases from elsewhere. By 1990, she had a major exhibition at MoMA, and throughout the decades has continued to push boundaries with her seemingly limitless approach to materials. But in 2015, she turned to painting, showing her first nine-feet-tall canvases at the Venice Biennale, and this month will present a major exhibition – that considers the entirety of her painting practice – at the Metropolitan Museum of Art here in New York – where we are recording today. Titled “Source Notes”, it will feature Simpson's monumental and spellbinding paintings, which, steeped in monochromatic blues, silvers, blacks and greys, appear in settings that evoke the cosmological or natural world. An extension of her photographic work, Simpson's paintings see the manipulated figure and body pressed into landscapes akin to waterfalls or meteorites, and I can't wait to find out more… https://lsimpsonstudio.com/ Lorna Simpson: Source Notes –  https://www.metmuseum.org/exhibitions/lorna-simpson-source-notes?utm_source=google&utm_medium=cpc&utm_campaign=&utm_term=lorna%20simpson%20art&utm_content=39536&mkwid=s&pcrid=743882408399&pmt=b&pkw=lorna%20simpson%20art&pdv=c&slid=&product=&gad_source=1&gad_campaignid=22399716678&gbraid=0AAAAADmlGN7UtMbglt7UAR4dicGAOa9Vx&gclid=CjwKCAjw24vBBhABEiwANFG7ywIA72_JjPaxVUdfQSWW_h8NFYNWzddlSHz6KV38M9zgiG4rs_9UNxoCVFkQAvD_BwE https://www.hauserwirth.com/artists/2860-lorna-simpson/ -- THIS EPISODE IS GENEROUSLY SUPPORTED BY THE LEVETT COLLECTION: https://www.famm.com/en/ https://www.instagram.com/famm_mougins // https://www.merrellpublishers.com/9781858947037 Follow us: Katy Hessel: @thegreatwomenartists / @katy.hessel Sound editing by Mikaela Carmichael Music by Ben Wetherfield

Another food poisoning outbreak linked to McDonalds several months ago has taken a sinister new twist. One person died and 104 got infected by E. coli they caught from a popular menu-meal item sold at McDonald's restaurants. According to the CDCs National Center for Emerging Infectious Diseases, outbreaks, hospitalizations and deaths from E. coli are on the rise. A new studythis week from researchers at the University of California San Diego believethey've found a potential link between E. coli and colon cancer. Move Over, Meditation ‘New Wellness' Trend Taking Over TikTok' Meet Bed Rotting: Gen Z's viral obsession with spending entire days marinating in bed, doomscrolling and calling it ‘self-care.' Supporters say it's a mentalhealth reset; critics say it's glorified burnout with a side of crumpled Cheeto dust. Is this the ultimate recharge hack… or just a fancy term for avoiding adulthood? We dig into science (and the snacks) behind the movement.Dr. Bob and Dr. Brockman take calls and emails from listeners

Lorlatinib is reshaping first-line treatment for ALK-positive NSCLC—but its distinct side effect profile demands proactive, personalized management. In this episode,  Stefanie Houseknecht, PharmD, BCOP (Johns Hopkins Medicine) and Monica Chintapenta, PharmD, BCOP (Parkland Health)share how they're navigating real-world use of lorlatinib, from interpreting long-term data to counseling patients through CNS effects, weight gain, and metabolic challenges.Highlights:Why lorlatinib is gaining traction in first-line ALK+ NSCLCWhat the long-term CROWN data really means for patient outcomesHow to handle tricky side effects like cognitive changes, weight gain, and hyperlipidemiaReal-world tips for patient counseling and supporting adherenceThe importance of catching drug interactions and staying ahead on labsHow pharmacists are shaping care across the oncology teamBonus: Hear how our guests find balance beyond the clinic, whether in the garden or on the Boston marathon course. About Our Guests:Monica completed her Doctor of Pharmacy at Texas Tech University Health Sciences Center and went on to complete PGY-1 and PGY-2 residencies at Tufts Medical Center and Froedtert & the Medical College of Wisconsin, respectively. At Parkland, she supports outpatient hematology/oncology care and leads quality initiatives.   Stefanie earned her PharmD from the University of the Pacific, followed by PGY-1 and PGY-2 residencies at Palomar Medical Center and the University of California-San Diego. Her work focuses on thoracic malignancies, access to oral targeted therapies, and patient outcomes. She is active in the International Association for the Study of Lung Cancer and serves as a preceptor to pharmacy trainees across the Mid-Atlantic.  

When our good friends encounter challenges,A default response for many of us is often:To have their backTo show up fullyTo be kindTo put judgment aside, And to remind them that they are not alone. When we turn this practice, of being for someone, toward ourselves, particularly in the face of:obstacles, hardships, adversity, and failure,it's called self-compassion.A practice that involves recognizing our own suffering, and meeting it with love, As we learn to become a good friend to ourselves. Over time learning to listen less to the harsh whispers of the inner critic, And more to the encouraging words from that wiser part of us - Our inner ally.When we practice in this way, the door to a more sustainable and expansive experience opens, And we have the opportunity to walk through it and into the rest of our life with greater resilience, ease, wellbeing, and balance.Today's guest, Megan Prager, is Director of Compassion Programs at the University of California San Diego's Center for Mindfulness. Megan is one of the leading teachers of mindful self compassion in the US.She hosts retreats, classes, and experiences that offer the opportunity to learn mindfulness, compassion, and a whole host of practices that foster an opportunity to learn to become better friends to ourselves. Today we are going to take a deep dive into Megan's journey to becoming the teacher and leader she is today. A journey that was marked by her own experiences of adversity, suffering, and (particularly at the beginning) skepticism of the very practices she now teaches.We'll also get into the fiercer aspects of self-compassion that involve:Boundary setting, Fnding the courage to show up in integrity, And how self-compassion can be helpful in the challenging and uncertain times we find ourselves in. For more on Megan, her classes, retreats, teacher trainings, and various other offerings, please visit mindfullabs.comDid you find this episode inspiring? Here are other conversations we think you'll love:On Wholeness, Service, and Enduring Happiness | Stephanie HarrisonEmbracing the Journey From 'Doing' to 'Being' with Amy DongEnjoying the show? Please rate it wherever you listen to your podcasts. Thanks for listening!Support the show

Premiums are rising. Insurers are leaving markets. But people keep building in risk-prone areas, and the climate disasters just keep coming. Can insurance markets adapt? In this episode, Shayle talks to Dr. Judd Boomhower, an assistant professor of economics at the University of California-San Diego and a faculty research fellow at the National Bureau of Economic Research. He studies how insurance markets are reacting to climate change. Shayle and Judd cover topics like: Why insurers are limiting coverage in California, Florida, and other high-risk markets How disaster insurance, unlike auto or health insurance, faces a flood of claims all at the same time How catastrophe models (or “cat models” for short) work and why AI and other improvements struggle the solve the fundamental problem: a lack of historical data needed to predict future events The challenges of private “black-box” catastrophe models that can't be reviewed by third parties Reinsurance markets and why they're not attracting more capital to shore up insurers The pros and cons of parametric insurance, an emerging category of insurance products Undercapitalized “fly-by-night” insurers that risk insolvency and failing to pay out claim Recommended resources NBER: How Are Insurance Markets Adapting to Climate Change? Risk Classification and Pricing in the Market for Homeowners Insurance Brookings: “How is climate change impacting home insurance markets?” Credits: Hosted by Shayle Kann. Produced and edited by Daniel Woldorff. Original music and engineering by Sean Marquand. Stephen Lacey is executive editor. Catalyst is brought to you by Anza, a platform enabling solar and storage developers and buyers to save time, reduce risk, & increase profits in their equipment selection process. Anza gives clients access to pricing, technical, and risk data and tools that they've never had access to before. Learn more at go.anzarenewables.com/latitude. Catalyst is brought to you by EnergyHub. EnergyHub helps utilities build next-generation virtual power plants that unlock reliable flexibility at every level of the grid. See how EnergyHub helps unlock the power of flexibility at scale, and deliver more value through cross-DER dispatch with their leading Edge DERMS platform, by visiting energyhub.com.

There have been several headlines over the past week about an AI chatbot officially passing the Turing test. These news reports are based on a recent preprint study by two researchers at the University of California San Diego in which four large language models (LLMs) were put through the Turing test. One model, OpenAI’s GPT-4.5, was deemed indistinguishable from a human more than 70% of the time.

Cybersecurity remains a top concern for many healthcare organizations as attacks continue to increase. On today's Monday episode of the Gist Healthcare podcast, we hear the second part of host J. Carlisle Larsen's conversation with Christian Dameff, MD, emergency physician and Co-Director of the University of California-San Diego's Center for Healthcare Cybersecurity, about takeaways from last year's cyberattack on the Change Healthcare clearinghouse and how proposed federal legislation regarding healthcare cybersecurity could impact hospitals, especially in rural areas. You can listen to the first half of the conversation here. Hosted on Acast. See acast.com/privacy for more information.

The healthcare industry remains the most targeted sector for cyberattacks in the United States. Last year had the dubious distinction of having the most patient records exposed in a year at more than 276 million. It also had the largest healthcare cyberattack on record, when UnitedHealth Group's Change Healthcare was hacked in February. Though we know that hospitals, vendors, and related organizations are particularly vulnerable to attacks, it's been difficult to fully secure them. Christian Dameff, MD, emergency physician and Co-Director of the University of California-San Diego's Center for Healthcare Cybersecurity, joins host J. Carlisle Larsen to talk more about challenges facing the industry and some common misconceptions about the motivations behind these attacks. This is a two-part episode. The second half of their conversation will air on Monday, April 7. Hosted on Acast. See acast.com/privacy for more information.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Learning more about the FDA letter sent to Dexcom, news from ATTD including a bihormonal pump from a Dutch company, time in tight range update, more studies about using insulin and GLP-1 medications, eating chili to prevent gestational diabetes (really!) and more..  Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Our top story this week: Dexcom Dive Brief: A warning letter posted Tuesday by the Food and Drug Administration revealed quality control issues with Dexcom's continuous glucose monitors. The FDA raised concerns with a design change to a component used in the resistance layer of Dexcom's sensors. The sensors with the new component were less accurate than those with the original component, according to the warning letter. Dexcom has ceased distribution of G7 sensors with the component, but the company's response did not address affected G6 sensors. J.P. Morgan analyst Robbie Marcus wrote in a research note Tuesday that the letter concerns a chemical compound that the sensor wire is dipped in. Dexcom began producing the compound internally to add redundancy to its supply chain.   Dive Insight: Dexcom Chief Operating Officer Jake Leach said in an interview with MedTech Dive last week that the company does not expect the warning letter to affect future product approvals, including a 15-day version of its G7 CGM, and there's no need yet to recall products. Dexcom has submitted the device to the FDA and anticipates a launch in the second half of the year.   Marcus, after speaking to company leadership and a quality control expert, wrote that many of the issues outlined in the letter could be addressed quickly. He added that the warning letter could explain minor delays in approval to the 15-day sensor, but Dexcom is still within the 90-day window for a 510(k) submission.   “While there's always a risk this could impede future product approvals,” Marcus wrote, “we do not expect this to materially delay the 15 day G7 sensor approval.”   The warning letter followed an FDA inspection last year of Dexcom's facilities in San Diego and Mesa, Arizona. Marcus wrote that after the FDA requested additional information and a separate 510(k), Dexcom stopped in-sourcing the compound and reverted back to the external supplier.   Dexcom's devices were misbranded because the company did not submit a premarket notification to the FDA before making major changes to the sensors, according to the warning letter. The sensors with the changed coating “cause higher risks for users who rely on the sensors to dose insulin or make other diabetes treatment decisions,” the letter said.     The FDA raised other concerns in the warning letter, including procedures to monitor the glucose and acetaminophen concentrations used in testing of the G6 and G7 CGMs. The FDA also cited problems with Dexcom's handling last year of a deficiency in its G6 sensors with dissolved oxygen content values, a key input for measuring blood glucose levels. https://www.medtechdive.com/news/dexcom-warning-letter-cgm-coating-change/743597/ XX Lots of studies and info out of the recent ATTD conference. One highlight that has been sort of under the radar: a Dutch company has been using a Bihormonal fully closed-loop system for the treatment of type 1 diabetes in the real world. This is a company called Inreda (in-RAY-duh). The Inreda AP® is an automatic system (closed loop) and independently regulates the blood glucose level by administering insulin and glucagon. The AP5 is certified in Europe and is being used in multiple studies and projects. The AP®6 is currently under development. https://www.inredadiabetic.nl/en/discover-the-ap/ https://pubmed.ncbi.nlm.nih.gov/38443309/ XX Let's talk about time in tight range. If you follow me and diabetes connections on social, you likely saw a video I made about this – it blew up last week. If not.. time in range has been a metric for a short while now.. in 2019 there was a consensus report advising a goal of 70% of time in the 70-180 mg/dL range for most people with type 1 diabetes (T1D) and type 2 diabetes (T2D), with modifications for certain subgroups. Recently we've been hearing more about 70-140 mg/dL — for longer periods as “time in tight range (TiTR).” At ATTD there was more talk about calling that range TING, or “time in normal glycemia.     There's a great writeup that I'll link up from the great Miriam Tucker on Medscape about a debate that happened at ATTD. On March 22, 2025, two endocrinologists debated this question at the Advanced Technologies & Treatments for Diabetes (ATTD) 2025. Anders L. Carlson, MD, medical director of the International Diabetes Center (IDC), Minneapolis, took the positive side, while Jeremy Pettus, MD, assistant professor of medicine at the University of California San Diego, who lives with T1D himself, argued that it's too soon.   https://www.medscape.com/viewarticle/should-time-tight-range-be-primary-diabetes-goal-2025a100073q?form=fpf   XX Sequel Med Tech announces its twist pump will be firs paired with Abbott's FreeStyle Libre 3 Plus. The twist has FDA approval for ages 6 and up and is set to begin its commercial launch by the end of June. The pump—designed by inventor Dean Kamen's Deka Research & Development—also incorporates the FDA-cleared Tidepool Loop software program, to record CGM blood sugar readings, make predictions based on trends and adjust its background insulin levels accordingly. https://www.fiercebiotech.com/medtech/sequel-med-tech-connects-twiist-insulin-pump-abbotts-cgm-ahead-market-debut XX Dexcom's longer-lasting CGM sensor looks promising, based on study results presented at the conference. The trial showed that the new 15-day G7 system is slightly more accurate than the current G7. The accuracy of CGM can be measured using MARD (mean absolute relative difference), which shows the average amount a CGM sensor varies from your actual glucose levels (a lower number is better).  The 15-day G7 has a MARD value of 8.0%, about the same as the Abbott Freestyle Libre 3. The Dexcom G7 15 Day is awaiting FDA approval and is not yet available in the U.S.   XX Little bit of news from Modular Medical.. they plan to submit their patch pump to the FDA late summer or fall of this year. The MODD1 product, a 90-day patch pump, features new microfluidics technology to allow for the low-cost pumping of insulin. Its new intuitive design makes the product simple to use and easier to prescribe. It has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery. Modular Medical picked up FDA clearance for MODD1 in September. The company also raised $8 million to end 2024. Its founder, Paul DiPerna, previously founded leading insulin pump maker Tandem Diabetes Care. DiPerna invented and designed Tandem's t:slim pump. By developing its patented insulin delivery technologies, the company hopes to improve access to glycemic control. Its founder, Paul DiPerna, previously founded leading insulin pump maker Tandem Diabetes Care. DiPerna invented and designed Tandem's t:slim pump. https://www.drugdeliverybusiness.com/modular-medical-announces-12m-private-placement/ XX More from attd – type 2 news? https://www.drugdeliverybusiness.com/biggest-diabetes-tech-news-attd-2025/ XX Another study that says people with type 1 who use a GLP-1 medication get better outcomes. In this study, those who use GLP-1 with insulin are 55% less likely to have a hyperglycemia-related ED visit, 26% less likely to have an amputation-related visit, and 29% less likely to have a diabetic ketoacidosis (DKA)-related ED visit in the following year compared to those on insulin alone. Although they are not approved for T1D, some patients may receive them off-label or for weight control. Pretty big study for an off label drug: compared 7,010 adult patients with T1D who were prescribed GLP-1s and insulin to 304,422 adult patients with T1D who were on insulin alone.  It is important to note that the rates of new diabetic complications in one year for both groups were around 1%, indicating that these are uncommon outcomes regardless of medication use. https://www.epicresearch.org/articles/some-diabetic-complications-less-likely-among-type-1-diabetics-on-glp-1s   XX Early research here but exposure to antibiotics during a key developmental window in infancy may stunt the growth of insulin-producing cells in the pancreas and boost risk of diabetes later in life The study, is published this month in the journal Science, it's a study in mice. These researchers are working off the idea that when while identical twins share DNA that predisposes them to Type 1 diabetes, only one twin usually gets the disease. She explained that human babies are born with a small amount of pancreatic “beta cells,” the only cells in the body that produce insulin.   But some time in a baby's first year, a once-in-a-lifetime surge in beta cell growth occurs.   “If, for whatever reason, we don't undergo this event of expansion and proliferation, that can be a cause of diabetes,” Hill said.   They found that when they gave broad-spectrum antibiotics to mice during a specific window (the human equivalent of about 7 to 12 months of life), the mice developed fewer insulin producing cells, higher blood sugar levels, lower insulin levels and generally worse metabolic function in adulthood.   in other experiments, the scientists gave specific microbes to mice, and found that several they increased their production of beta cells and boosted insulin levels in the blood. When male mice that were genetically predisposed to Type 1 diabetes were colonized with the fungus in infancy, they developed diabetes less than 15% of the time. Males that didn't receive the fungus got diabetes 90% of the time. Even more promising, when researchers gave the fungus to adult mice whose insulin-producing cells had been killed off, those cells regenerated. Hill stresses that she is not “anti-antibiotics.” But she does imagine a day when doctors could give microbe-based drugs or supplements alongside antibiotics to replace the metabolism-supporting bugs they inadvertently kill.   .   “Historically we have interpreted germs as something we want to avoid, but we probably have way more beneficial microbes than pathogens,” she said. “By harnessing their power, we can do a lot to benefit human health.”     https://www.eurekalert.org/news-releases/1078112 XX Future watch for something called BeaGL - created by researchers at the University of California Davis and UC Davis Health who were inspired by their own personal experiences with managing T1D.   BeaGL is designed to work with CGMs and has security-focused machine learning algorithms to make predictive alerts about anticipated glucose changes, which are sent to a device. In this case, a smartwatch. The end goal is for BeaGL to be completely automated to reduce the cognitive load on the patient, particularly for teens. It's still in research phase but six student with T1D have been using it for almost a year.     https://health.ucdavis.edu/news/headlines/with-ai-a-new-metabolic-watchdog-takes-diabetes-care-from-burden-to-balance/2025/02 XX Investigators are searching for a way forward after two long-term diabetes programs were terminated following the cancellation of their National Institutes of Health (NIH) funding, the result of federal allegations that study coordinator Columbia University had inappropriately handled antisemitism on campus. The programs include the three-decades-old Diabetes Prevention Program (DPP) and its offshoot, the Diabetes Prevention Program Outcomes Study (DPPOS). “We are reeling,” said David Nathan, MD, a previous chair of both the DPP and the DPPOS and an original leader of the landmark Diabetes Control and Complications Trial. Nathan is also founder of the Massachusetts General Hospital Diabetes Center in Boston, one of the 30 DPPOS sites in 21 states. On March 7, the Trump administration cancelled $400 million in awards to Columbia University from various federal agencies. While Columbia University agreed on March 21 to changes in policies and procedures to respond to the Trump administration's charges, in the hopes that the funding would be restored, DPPOS Principal Investigator Jose Luchsinger, MD, told Medscape Medical News that as of press time, the study was still cancelled. https://www.medscape.com/viewarticle/diabetes-prevention-program-cancellation-colossal-waste-2025a100076h XX XX Type 2 diabetes may quietly alter the brain in ways that mimic early Alzheimer's. This was only an animal study – but researchers say the high comorbidity of type 2 diabetes (T2D) with psychiatric or neurodegenerative disorders points to a need for understanding what links these diseases.   https://scitechdaily.com/how-diabetes-quietly-rewires-the-brains-reward-and-memory-system/ XX Eating chili once a month when you're pregnant seems to lower the risk of developing gestational diabetes. This is a real study! While chili showed a link to lower gestational diabetes risk, dried beans and bean soup had no significant effect, even among women who ate them more frequently. Some studies suggest that diets high in beans and legumes, including the Mediterranean diet, reduce GDM risk. While studies link beans to lower diabetes risk, their specific impact on GDM remains unclear. This study analyzed data from 1,397 U.S. pregnant women who participated in the Infant Feeding Practices Study II, conducted between 2005 and 2007. Chili consumption varied significantly by race, education, household size, income, supplemental nutrition status, and region. Non-Hispanic Black mothers consumed the most (0.33 cups/week), while those with higher income and education levels consumed less. Regional differences also influenced chili intake. One possible mechanism for chili's effect is capsaicin, a bioactive compound found in chili peppers, which has been linked to metabolic benefits in other studies. However, further research is needed to confirm this potential role in GDM prevention. Dried bean and bean soup consumption had no clear association with GDM. The study highlights limitations due to self-reported dietary data and the need for more detailed dietary measures. https://www.news-medical.net/news/20250317/Could-a-little-spice-in-your-diet-prevent-gestational-diabetes.aspx XX

Invitado: Dr. Rafael Fernández de Castro, Director del Centro de estudios México-Estados Unidos de la Universidad de California San Diego.Conduce: Dr. Miguel Ángel Valverde, Director del Centro de Investigación Internacional del IMR.

Republican Missouri Rep. Peggy McGaugh wants to allow someone to serve up to 16 years in either the House or the Senate. Currently, most legislators can serve up to eight years in the House and eight in the Senate. McGaugh discusses her proposal on the Politically Speaking Hour on St. Louis on the Air. Then, term limits expert Thad Kousser, a political science professor at the University of California-San Diego, discusses the history and trends behind term limits in the U.S.

On the latest episode of the Politically Speaking Hour on St. Louis on the Air, STLPR's Jason Rosenbaum explores the pros and cons of Missouri's legislative term limits. He talked with state Rep. Peggy McGaugh, who wants to allow someone to spend up to 16 years in the Missouri House or the Missouri Senate. And he also discussed term limits throughout the country with University of California-San Diego political science professor Thad Kousser. Rosenbaum also checked in with GOP Rep. Eric Burlison about the lay of the land in Washington, D.C.

JCO PO author Dr. Hatim Husain at University of California San Diego, shares insights into his JCO PO article, “Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRASG12C-Mutated Non–Small Cell Lung Cancer: A Case Series and Literature Review”, one of the top downloaded articles of 2024. Host Dr. Rafeh Naqash and Dr. Husain discuss how to utilize real-world and clinical trial data to discern the safety of adagrasib (another KRASG12C inhibitor), following sotorasib discontinuation due to hepatotoxicity. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations where we bring you engaging conversations with authors of clinically relevant and highly significant JCOPO articles. I'm your host, Dr. Rafeh Naqash, Podcast Editor for JCO Precision Oncology and Assistant Professor at the OU Stephenson Cancer Center.  Today, I'm very excited to be joined by Dr. Hatim Hussain, Professor of Medicine at the University of California, San Diego, and author of the JCO Precision Oncology article, “Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRAS-G12C-Mutated Non-Small Cell Lung Cancer: A Case Series and Literature Review.” This was one of the top downloaded articles of 2024. And the other interesting thing is we generally don't do podcasts for case reports or case series, so this is one of the very few that we have selected for the podcast.  And at the time of the recording, our guest disclosures will be linked in the transcript.  Dr. Hussain, welcome to our podcast and thank you for joining us today. Dr. Hatim Husain: Thank you Dr. Naqash. Such a pleasure to be here and to speak with you all. Dr. Rafeh Naqash: And for the sake of this podcast, we'll refer to each other using our first names. So again, as I mentioned earlier that this is one of the very few case reports that we have selected for podcasts in JCOPO and the intention was very deliberate because it caters to something that is emerging where we are trying to treat more KRAS mutant patients with different KRAS inhibitors. And you tried to address one very unique aspect of it in this article which pertains to toxicity, especially hepatotoxicity. So for the sake of our listeners who tend to be community oncologists, trainees, academic faculty, can you tell us what are KRAS inhibitors? What is KRAS-G12C? And how do some of these approved KRAS inhibitors try to inhibit KRAS-G12C? Dr. Hatim Husain: Sure. For a long time actually we've not had a selective way to inhibit mutant KRAS. And over the last several years actually now, we've seen some dramatic advances here, particularly with the FDA approval of some of the selective inhibitors against the G12C variant. So KRAS-G12C is an isoform of KRAS that is most common in lung cancer and in fact actually is a transversion mutation in the KRAS gene that is a product of the carcinogen of tobacco. And in fact, the incidence of KRAS-G12C in lung cancer, it's quite astounding where as many KRAS-G12C patients there are, there can be, as you know, more than EGFR patients in certain populations and cohorts. The medicines sotorasib and adagrasib were rationally designed to be selective KRAS-G12C inhibitors. And the way that they do this is that they lock the KRAS protein in the OFF state. KRAS is a protein that oscillates between an ON and an OFF state and by virtue of locking the protein in an OFF state, it has shown inhibition of downstream signaling and mitigation of tumor growth and, in fact, tumor cell death. Dr. Rafeh Naqash: I absolutely love the way you describe the ON and OFF state, the oscillation where the ON is bound to the GTP and the OFF is bound to the GDP. The two KRAS inhibitors as currently FDA approved, as you mentioned, are RAS OFF inhibitors and they're emerging KRAS inhibitors that are RAS ON. So now, as we have known from previous data related to immunotherapy and EGFR TKIs such as osimirtinib where toxicity tends to be a compounded effect when you have osimertinib given within a certain timeline of previous checkpoint therapy, we've seen that in the clinic as the data for these KRAS inhibitors is emerging, you talk about some very interesting aspects and data about what has been published so far with regards to prior use of immunotherapy or chemo immunotherapy and the subsequent use of KRAS inhibitors. Could you elaborate upon that? Dr. Hatim Husain: Sure. So for this population of patients, the first line approved strategy is a strategy that most cases will incorporate immune therapy and chemotherapy. Immune therapy can have some important responses for patients with KRAS-G12C. This may be due to the fact that KRAS-G12C patients may have a higher incidence of prior smoking, perhaps higher mutation burdens in some patients, and perhaps immunogenicity is defined in that context. So the standard of care in the first line currently includes immune therapy or immune therapy and chemotherapy. Where the current FDA approvals for selective G12C inhibitors are are after the first line of therapy. There are a number of trials exploring these medicines in the first line to see if they may be incorporated into a future treatment paradigm. Dr. Rafeh Naqash: Thank you for that explanation. Now, going to what you published in this manuscript, can you help us understand the context of why you looked at this? Even though the data just comprises a case series of a handful of patients, but the observations are very interesting and these are real world scenarios where we often tend to be in situations where an individual has had toxicity on a certain drug and may have some response to that drug, but at the same time, the toxicity is challenging. And then you try to debate whether another drug in the same class might be beneficial without those toxicities. So you've tried to address that to some extent using this data set. So can you elaborate upon the question, the methodology, what you tried to look at, and important observations that you have? Dr. Hatim Husain: Yes, our paper was actually inspired by one of my patients. My patient was a patient who had received chemotherapy and immune therapy and actually in the past, even, you know, additional lines of immune therapies, it was really coming to the edge of where standard treatments would exist. It was right at the same time that these selective inhibitors had been approved and the patient had received sotorasib. And what was remarkable was, when given sotorasib, patient had a very high peak and spike in the transaminases. And we would do different trials of strategies around dose, around interruptions. And it was becoming quite difficult, actually, for the patient to proceed with additional therapy. It was around similar times, actually, and I do want to make a note that the patient was progressing, driven in large fact by the fact that we've had to interrupt the medicine. So we feel and believe that the patient had had inadequate dosing because of the level of toxicity that the patient was having with transaminase increase. So it was around the same time that adagrasib was first commercially available that we were at that point, and we did a trial of adagrasib post-sotorasib, largely driven by necessity, without having additional options to provide this patient in our environment. What was remarkable was when the patient received the adagrasib, there were no spikes in transaminases similar to what we had seen before. And that really led us thinking and to say, “Is this adverse event of transaminase increase or hepatotoxicity, is this a class effect with KRAS-G12C inhibitors, or is it more nuanced than that? Are there different, perhaps, mechanisms by which the medicines may work that may more or less differentially contribute to this adverse event?” And so that inspired us to kind of do a larger analysis, kind of really reach out to a larger network of physicians to gather insights and to gather responses in patients who had had a serial approach of sotorasib and then adagrasib.  What we found in this process was, in fact, actually there were many more cases of patients who resembled my patient, where the sequence of sotorasib going to adagrasib may have demonstrated differential contribution of hepatotoxicity in that context. And that really motivated us to put the publication together to due diligence, and in the publication spend a lot of time to kind of outline each patient case in detail around metrics surrounding time from last immune therapy, the number of days on sotorasib, the best response to sotorasib, the interval between sotorasib and adagrasib, the duration of adagrasib and then the grade of hepatotoxicity seen in each of the contexts, and particularly kind of the adagrasib and patient disease status as well. We were quite inspired by the effort to try to, if we do not have randomized data in comparison of one medicine to another, which we do not at this juncture, we do not have a randomized analysis to really diligently and rigorously compare the rates of AEs across each medicine, and even in sequence, we do not have that with immune therapy. But what we felt was trying to get more analysis of this sequential approach of, if patients had received a medicine, had to be taken off because of toxicity and then actually tried on a new medicine, what were those rates? We felt like that was at least some information to try to get at this question. Dr. Rafeh Naqash: And you bring forward a very important point, which is, a lot of times in the real world setting we don't have cross trial comparisons that can be fully applicable, or we don't have trials that compare two drugs of the same class with respect to the AE profile or efficacy. And observations like the one that you described that led to this study are extremely critical in trying to help answer these questions.  From a data standpoint, and you allude to it to some extent in your manuscript, the trials that are trying to address combination of KRAS-G12C with immunotherapy, especially sotorasib or adagrasib, can you elaborate on that data, what has been published so far and summarize it for our listeners? Dr. Hatim Husain: So there is data from clinical trials looking at patients actually who have received concomitant immune therapy and sotorasib. What was seen in this, in a real world analysis, was that some patients actually who had received sotorasib within a close proximity of immune therapy, as well as a larger study actually which showed in combination there were higher rates of hepatotoxicity in that context. In fact, there were rates of grade 3 hepatotoxicity. And I think built upon that data there's a recognition in the field that we have to be very diligent in terms of even the clinical trial designs in how to understand the pairing between immune therapy and selective G12C inhibitors. There are many trials that are ongoing, one of the studies that is ongoing is known as the KRYSTAL-7 study, which is evaluating adagrasib in combination with pembrolizumab in the first line. And we await more information on that strategy as well. In the context of sotorasib, because of some of the trials that have shown higher rates of hepatotoxicity, there are some additional trials now looking at sotorasib in combination with chemotherapy, and those also have some information that have been reported as well. Dr. Rafeh Naqash: From a drug development standpoint, as you mentioned, there's always a tendency to combine something with something else. And in my practice, and I'm sure in your practice too, when we do early phase trials, many trials are still focused on choosing the maximum tolerated dose, which may be something that we need to gradually move away from as we try to implement these combinations of multiple antibodies plus some of these target agents from maybe the biological optimal dose rather than the maximal tolerant dose is a better way to look at the drugs, the pharmacokinetic profile, and then see what is likely the safest combination with the most appropriate target engagement. Do you have any thoughts on that or insights on that from a drug development perspective? Dr. Hatim Husain: It's a wonderful question and I think it is a very insightful question and understanding of where we are in space right now. And I agree with you that historically, cancer drug development was really hinged upon medicines that perhaps required higher doses to see a benefit or to inch out kind of marginal increases upon where we were at. Now, in combination with medicines that have non-overlapping mechanisms of action, the concept is: Can there actually be more synergy across an approach using combinatorial strategies rather than just additive effects? And I think that in some cases this is being studied with immune therapy, in some cases actually even in the context of other novel mechanisms for cancer therapy. I think that in my practice, I will really try to see how a patient at an approved dose will respond. But definitely I'm open to the concept that there may be a dose that doesn't have to be the maximally tolerated dose, but rather the dose that responses can be seen and perhaps actually at a lower dose than what drives many toxicities. Dr. Rafeh Naqash: I often describe this to my patients as individual patient dose optimization outside of a clinical trial, where I'm sure you've probably done this, where in older adults maybe a lower dose of osimertinib is tolerated better, or a lower dose of sotorasib or adagrasib for that matter, tolerated better with perhaps a similar level of efficacy, since we don't have comparisons between doses and efficacy so far.  So I think in the bigger picture, as we discussed in a nutshell, what I would really like the listeners to understand is as we try to move towards this field of precision medicine targeting more and more of the undruggable genes, there's bound to be a certain level of toxicity patterns that we'll start observing. So I think these real world scenarios which may not be addressed using clinical trials because it is in the real world setting where you cycle one treatment after another after another, which may or may not be allowed in most trials and the real world setting can inform, in certain cases, subsequent trial designs. So I think the most important message, at least that I took from your manuscript, was that these real world observations can make a huge difference and inform practice, even though the data sets may be small. Of course, you want to validate some of these findings in a bigger, broader setting, but proof of concept is there. And I think next time I see an individual in my clinic where I see better toxicity, I'll definitely try to talk to them about subsequent treatment with another KRAS inhibitor, maybe adagrasib or something else, if and when appropriate.  Do you have any closing thoughts on some of these things that we discussed? Dr. Hatim Husain: I just want to leave the audience actually with this concept that sometimes we group targeted therapy side effects as being class effects unanimously. And I do think actually that each inhibitor may have different off target effects on where medicine may act. We don't truly understand the mechanism of hepatotoxicity in the context of selective KRAS-G12C inhibitors. One of the hypotheses may be due to off target cysteine reactivity in the numerous off target binding sites that certain medicines may have over others. And just even qualitatively which off target binding sites there may be, and how that may lead to either immunogenic responses and other organs or such. So I do think that we do need more research to understand the mechanism. But I think where we are at right now in this space is not assuming that all medicines are going to have the exact same toxicity. I think especially when patients may not have other options, this is something to consider as well. Dr. Rafeh Naqash: Thank you so much. Now, outside of the scientific insights, Hatim, I know you a little bit from before. And knowing the kind of work that you've done in precision medicine, I'm really interested to know about where you started, how you started, how things have been, and what kind of advice you have for junior faculty fellows who are interested in this field of precision medicine that is becoming more and more exciting as we progress in the oncology space. Dr. Hatim Husain: Thank you, Rafeh. I will say, actually as a medical student, I was actually very interested in oncology, partly because it was then and still remains one disease or a constellation of diseases that just has such a high psychological burden on patients. And through the experiences I've had, I really can understand and relate with that concept. I did my medical school at Northwestern, residency at the University of Southern California, and then my oncology fellowship at Johns Hopkins University.  And now I've been on faculty at University of California, San Diego, for about 12 years now. It's been a great experience paralleled with the fact that during these last 12 years, I've really seen how the developments in precision oncology, both targeted therapy as well as immune therapy, have really blossomed and unfolded. A large area of my research in my career has kind of focused on cancer genome and integration of novel technologies to really see how they may have clinical application. When I was in my fellowship and as a young faculty, the liquid biopsy was actually coming into development. And this was hinged upon information that had come forward in the prenatal space where some patients actually who were undergoing prenatal testing during pregnancy were found to have complex karyotypes and genomic alterations and then retrospectively found to have cancer.  And doing my fellowship at Johns Hopkins, some of the pioneers in liquid biopsy were my mentors and really kind of instilled in me that passion for really thinking through how cancer genomics can be integrated through time. And some of the research that I have been doing has been looking at clonal evolution of cancer, how cancer is changing over time, and how we can think through the right surveillance strategies to really understand how that change is occurring. The dynamics of ctDNA in retrospective cohorts have been studied and shown that, you know, there can be associations between progression-free survival and other clinical endpoints. The current paper that we are speaking about parallels that in a certain way where, rather than say, looking at clonal evolution and say, the efficacy answer of sotorasib first and then adagrasib and how frequently can adagrasib salvage patients, this looks at it from a different angle around toxicity. And I think that is a key point because, at my core, I really do enjoy the clinical aspect of complex decision making on behalf of patients weighing efficacy and toxicity that they may have as they try to get the best quality of life through this journey. Dr. Rafeh Naqash: Thank you again, Hatim, for all those insights, both from the scientific perspective as well as personal perspective. We appreciate that you chose JCOPO as the destination for your work.  And thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Dr. Hatem Husain Disclosures Consulting or Advisory Role: AstraZeneca, Foundation Medicine, Janssen, NeoGenomics Laboratories, Mirati Speakers' Bureau: AstraZeneca, Janssen Institution Research Funding: Pfizer, Bristol-Myers Squibb, Regeneron, Lilly Travel, Accommodations, Expenses: AstraZeneca, Janssen, Foundation Medicine  

Niemand Geringeres als Dr. Joe Dispenza, einer der revolutionärsten Köpfe unserer Zeit, ist zu Gast in unserem Podcast! Dr. Joe Dispenza enthüllt in diesem faszinierenden zweiten Teil des Interviews, wie Du Deine Zirbeldrüse aktivieren und tiefe transformative Erfahrungen machen kannst. Erfahre, welche Rolle die Zirbeldrüse als biologisches „Antennensystem“ spielt und wie sie Deine Wahrnehmung und Dein Bewusstsein erweitert. Dr. Dispenza erklärt, wie Meditation gezielt genutzt werden kann, um die Verbindung zwischen Gehirn und Herz zu stärken und den Körper in einen Zustand der Heilung zu versetzen. Begleite uns auf eine Reise in die tieferen Ebenen des Bewusstseins und entdecke, wie Du Dein volles Potenzial entfalten kannst. Ein Gespräch, das die Grenzen von Wissenschaft und Spiritualität neu definiert. SOURCE - Der Film: https://sourcethefilm.org/ Mehr über Dr. Joe Dispenzas Arbeit: https://drjoedispenza.com/ Dr. Joe Dispenza, ein New York Times-Bestsellerautor, Forscher, Dozent und Unternehmensberater, hat eine praktische Formel entwickelt, um Menschen dabei zu helfen, ihr Leben zu transformieren. Dr. Joes Mission vereint komplexe Wissenschaftszweige auf eine zugängliche Weise – mit Fokus auf fundierte Forschung, „Stories of Transformation“-Erfahrungsberichte und die wissenschaftlichen Daten hinter spontanen Remissionen. Inspiriert von den neuesten Erkenntnissen in den Bereichen Neurowissenschaft, Psychoneuroimmunologie, Epigenetik und Quantenphysik integriert seine Arbeit essenzielles Wissen über die Verbindung von Geist und Körper – und lehrt Menschen, wie sie verschiedene gesundheitliche Probleme heilen und bedeutende Veränderungen in ihrem Leben bewirken können. Seit 2010 arbeitet er mit renommierten Wissenschaftlern und Universitäten zusammen – darunter die University of California San Diego, Harvard University, Stanford University und andere – um umfangreiche Forschungen zu den Auswirkungen von Meditation auf Gehirn und Körper durchzuführen. Wie genial bist Du wirklich? Trainiere Dein Genie mit starken Videokursen aus unserer Online-Akademie: https://akademie.maximmankevich.com/   

Dean's Chat hosts, Drs. Jensen and Richey, welcome Dr. Gerit D. Mulder to the podcast!  Dr. Mulder gave Dr. Jensen an opportunity to join his practice at the Wound Healing Institute after residency, providing a tremendous foundation for future research that included the National Institutes of Health, and Department of Defense opportunities.  Dr. Mulder has a storied history in podiatric medical research in the wound care space.  He received his BS at University of Redlands; a masters degree from Cal State - San Bernadino, then received his DPM from the College of Podiatric Medicine. He received his PhD from Chulalongkorn University through University of California San Diego specializing in Biomedical Sciences/Stem Cells.  Gerit speaks 5 languages and has taught wound care, and implemented wound care programs around the world.  Tune in for a fabulous interview! Below is a brief history of Dr. Mulder's activities and qualifications: • Extensive expertise in the development, implementation and management of clinical trials, clinical operations and teams.  Experience as a lead Principal Investigator interacting with and guiding multicenter trials.  Direct interaction with the FDA, Pharmaceutical Industry and Academic Research Centers.  Focus on Inflammatory Diseases, Dermatology and Infectious Disease.  • Responsible for development and oversight than 120 clinical trials. • Supervised, educated, and guided research teams globally. • Developed project budgets, protocols, guidelines, and implementation plans for developing wound clinics. • Provided strategic and tactical input to the medical industry related to clinical trials with emphasis on Phase 1,2 and 3 studies.  • Created tissue and wound repair programs to increase product understanding to assist Emerging Markets. Additional Expertise and Affiliations Include: • Understanding of Regulatory Affairs. • International experience with monitoring and overseeing clinical trials. • Served as a national and international  • Provided input on new product development for novel disease states.  • Conversational skills in English, Spanish, Italian, French, and German • Extensive experience with KOLs and medical advisory boards. Physician at Christus St. Vincent Medical Center, Wound & Hyperbaric Center. December 2021 to current. • Provide advanced clinical care for chronic wounds of all etiologies including diabetic, venous, pressure, trauma and other wounds. • Direct wound and tissue repair and regeneration research Medical Research Consultant – Independent 2019 – current Clinical Tissue Repair and Regeneration Specialist – 2019-current • Consult internationally on Phase 1,2, and 3 clinical trials • Provide input for development and implementation of clinical trials and educational materials for health care providers related to phase 1, 2 and 3 studies as well as approved products. • Provide clinical care to patients with acute and chronic wounds of all etiologies Director, Professor of Surgery and Orthopedics University of California San Diego Medical Center, Wound Treatment and Research Center   April 1998- December 2013 •  Provided clinical and surgical care, conducted medical student, resident and staff education, oversaw clinical research.  Treated more than 3000 patients per year.  Published in peer reviewed medical journals and key presenter at medical conferences globally. • Oversaw research within my division of the Department of Trauma, with focus on tissue regeneration and repair, inflammatory and infectious related diseases and cell regeneration. June 1986-April 1998: President of WCI (Wound Consultants Inc., previously Wound Healing Institute)    WCI offered consulting services to the biotechnology and pharmaceutical industry related to clinical protocols and trials, implementation of related patient care, planning and managing medical education.  Advised on development of new products related to tissue regeneration and repair. Patient Care    Vice President of Marketing and Medical Affairs DermaRx  May 1995- March 1998 Vice President of Clinical and Regulatory Affairs Organogenesis, Inc.   May 1994-May 1995     Wound Clinic Director Veterans Administration Hospital Denver June 1983- Jne 1992 FDA Experience: • Participated as an advisor to the FDA and companies working with the FDA • Completed and submitted 510k for hydrogel, foam, and other wound treatment devices • Completed clinical section of PMA submission on Apligraf for Organogenesis • Consulted as wound care expert on panels for medical and pharmaceutical industry. • Chaired Human Subjects Committee in Denver for two years for a major IRB. • Interacted with FDA on Dermatology and Inflammatory Diesease Dr. Mulder can be reached at (619) 417-9249 or at gerit.mulder@gmail.com;  gerit.mulder@stvin.org  or on LinkedIn at http://www.linkedin.com/pub/gerit-mulder/a/321/6b5

Summary:  This week on The Genetics Podcast, Patrick is joined by Eric Adler, Chief Medical Officer and Head of Research at Lexeo Therapeutics and Professor of Medicine at University of California San Diego. Eric shares his experience with genetic cardiomyopathy and his work on gene therapy for Danon disease, drawing from both clinical and research perspectives. Additionally, he explores the evolution of the field and the broader challenges faced by cardiovascular patients. Show Notes:  0:00 Intro to The Genetics Podcast 01:00 Welcome to Eric and his efforts in cardiomyopathy at the bench and bedside 03:32 How modeling genetic diseases using pluripotent stem cells lead Eric to studying Danon disease  04:50 Pivoting from basic to translational research using adeno-associated viruses (AAV)-based gene therapy 07:58 Uncovering genetic cardiomyopathies that were misdiagnosed as idiopathic cardiomyopathy 09:55 Treatment, screening, and penetrance of Danon disease 12:30 Recent successes and remaining challenges in cardiovascular disease 19:47 Battling distrust in the medical profession 21:55 Preventative therapy using APOE2 for patients at risk of early Alzheimer's   25:15 Motivations behind and advantages of Eric's patient-centered approach to therapeutics 27:24 Balancing regulatory requirements for protocols versus patient needs 29:49 The importance of committed clinical partners for successful trial execution 36:08 Eric's passion for cooking and how he won a cooking competition 39:02 Closing remarks and Lexeo Therapeutics' aims for 2025 Find out more Lexeo Therapeutics (https://www.lexeotx.com/) Please consider rating and reviewing us on your chosen podcast listening platform!  https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link

In this episode of the Next Level Healing Podcast, Dr. Tara Perry interviews Dr. Hemal Patel, Professor & Vice Chair for Research, Dept. of Anesthesiology at the University of California San Diego. Dr. Patel is well-known for his work with Dr. Joe Dispenza and his role in the movie, Source: It's Within You. This is an episode you don't want to miss!Work with Dr. Tara PerryTune in every week for a new episode of Next Level Healing. Subscribe on your favorite podcasting platform and never miss an episode!

Podcasts, reviews, interviews, essays, and more at the Ancillary Review of Books.Please consider supporting ARB's Patreon!Credits:Guest: Hilary StrangTitle: Aurora by Kim Stanley RobinsonHost: Jake Casella BrookinsMusic by Giselle Gabrielle GarciaArtwork by Rob PattersonOpening poem by Bhartṛhari, translated by John BroughReferences:Marooned on Mars, a podcast about the works of KSRUrsula Le Guin's The DispossessedMargaret Killjoy's A Country of GhostsKSR's Mars trilogyFredric Jameson's Archaeologies of the FutureJohn Dos Passos's U.S.A. trilogyWiscon“The Hard Problem” audio project adaptation of a section of Aurora, created with Marina Abramović's workshop, mixed/composed by Adam Tinkle, with the Arthur C. Clarke Centre for Human Imagination at the University of California San Diego.Much of the web-available multimedia about this project is lost to time and linkrot, unfortunately, but there's a very nice write-up at this fan-run KSR site.You can still find a YouTube version of the audio here.As mentioned in the show credits, the “Into the Impossible” podcast later developed into something very different, platforming far-right whackjobs, climate deniers, TESCREALists, that kind of thing, along with lots of presumably credible scientists, so: be warned. I'm not clear on how the early “Into the Impossible” podcasts with the Clarke Centre transitioned to the later, longer-running show with Brian Keating; just don't want to accidentally contribute to any of you going down a brain-worm-inducing YouTube/podcast-algo spiral.Leyna Krow's Sinkhole, and Other Inexplicable VoidsTom Godwin's “The Cold Equations”“Wherever you go, there you are.”KSR's 2312 and New York 2140Sofia Samatar's The Practice, the Horizon, and the ChainTheodore McComb's UraniansGene Wolfe's Book of the Long SunStephen H. Dole's Habitable Planets for ManTracked it down: the "drop unconscious humans off on a grid to check habitability" thing is from Charlie Stross's excellent blog.C.J. Cherryh's Heavy Time"Enough is as good as a feast."Le Guin's “Mrs. Brown Test” is from “Science Fiction and Mrs. Brown” in The Languages of the NightKSR's Science in the Capital Trilogy, re-released as Green Earth"Science Fiction is the Realism of Our Times""True Voyage Is Return"The Alien filmsMary Shelley's Frankenstein

Dr Jessica Allen, lichenologist and cell biologist at the University of California San Diego, has studied lichen all over the world, including in Okanogan County! In the course of 45 fascinating minutes she sheds light on what exactly lichen are, their life history, and what makes them so unique and special. Having studied lichen for 17 years, she is uniquely qualified to inspire us all to dig in and discover the diverse, beautiful, and complicated world of lichens. Enjoy! Want to learn more? Check out this article from the New York Times (2021) featuring Jessica Allen: https://www.nytimes.com/2021/11/03/realestate/gardening-lichen-fall.html Find the Northwest Lichenologists at: https://northwest-lichenologists.wildapricot.org/ Lichen books recommended by Dr. Allen: Macrolichens of the Pacific Northwest (2024) by Bruce McCune, Linda Geiser Lichens of North America (2001) by Irwin M. Brodo, Sylvia Duran Sharnoff, Stephen Sharnoff  To learn more about and support Okanogan Highlands Alliance, visit: ⁠okanoganhighlands.org⁠

One long-time expert on preventing student cheating argues that understanding why students cheat is key to making adjustments in teaching to prevent cheating with AI. It's the argument of Tricia Bertram Gallant, a longtime expert in academic integrity who is director of the Academic Integrity Office at the University of California San Diego who co-wrote a new book, “The Opposite of Cheating: Teaching for Integrity in the Age of AI. See show notes at EdSurge.com: https://www.edsurge.com/news/2025-01-07-ai-has-changed-student-cheating-but-strategies-to-stop-it-remain-consistent

How do you keep the cracks in Starry Night from spreading? How do you prevent artworks made of hugs or candies from disappearing? How do you render a fading photograph eternal—or should you attempt it at all? These are some of the questions that conservators, curators, registrars, and exhibition designers dealing with contemporary art face on a daily basis. In Still Life: Ecologies of the Modern Imagination at the Art Museum (University of Chicago Press, 2020), Fernando Domínguez Rubio delves into one of the most important museums of the world, the Museum of Modern Art (MoMA) in New York, to explore the day-to-day dilemmas that museum workers face when the immortal artworks that we see in the exhibition room reveal themselves to be slowly unfolding disasters. Still Life offers a fascinating and detailed ethnographic account of what it takes to prevent these disasters from happening. Going behind the scenes at MoMA, Domínguez Rubio provides a rare view of the vast technological apparatus—from climatic infrastructures and storage facilities, to conservation labs and machine rooms—and teams of workers—from conservators and engineers to guards and couriers—who fight to hold artworks still. As MoMA reopens after a massive expansion and rearranging of its space and collections, Still Life not only offers a much-needed account of the spaces, actors, and forms of labor traditionally left out of the main narratives of art, but it also offers a timely meditation on how far we, as a society, are willing to go to keep the things we value from disappearing into oblivion. This interview is part of an NBN special series on “Mobilities and Methods.” Fernando Domínguez Rubio is an Associate Professor at the Department of Communication at the University of California-San Diego. Alize Arıcan is a PhD candidate in the department of Anthropology at the University of Illinois at Chicago. Her work focuses on urban renewal, futurity, care, and migration in Istanbul, Turkey. Nushelle de Silva is a PhD candidate in the Department of Architecture at the Massachusetts Institute of Technology. Her work examines museums and exhibitions, and how the dissemination of visual culture is politically mediated by international organizations in the twentieth century.   Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

How do you keep the cracks in Starry Night from spreading? How do you prevent artworks made of hugs or candies from disappearing? How do you render a fading photograph eternal—or should you attempt it at all? These are some of the questions that conservators, curators, registrars, and exhibition designers dealing with contemporary art face on a daily basis. In Still Life: Ecologies of the Modern Imagination at the Art Museum (University of Chicago Press, 2020), Fernando Domínguez Rubio delves into one of the most important museums of the world, the Museum of Modern Art (MoMA) in New York, to explore the day-to-day dilemmas that museum workers face when the immortal artworks that we see in the exhibition room reveal themselves to be slowly unfolding disasters. Still Life offers a fascinating and detailed ethnographic account of what it takes to prevent these disasters from happening. Going behind the scenes at MoMA, Domínguez Rubio provides a rare view of the vast technological apparatus—from climatic infrastructures and storage facilities, to conservation labs and machine rooms—and teams of workers—from conservators and engineers to guards and couriers—who fight to hold artworks still. As MoMA reopens after a massive expansion and rearranging of its space and collections, Still Life not only offers a much-needed account of the spaces, actors, and forms of labor traditionally left out of the main narratives of art, but it also offers a timely meditation on how far we, as a society, are willing to go to keep the things we value from disappearing into oblivion. This interview is part of an NBN special series on “Mobilities and Methods.” Fernando Domínguez Rubio is an Associate Professor at the Department of Communication at the University of California-San Diego. Alize Arıcan is a PhD candidate in the department of Anthropology at the University of Illinois at Chicago. Her work focuses on urban renewal, futurity, care, and migration in Istanbul, Turkey. Nushelle de Silva is a PhD candidate in the Department of Architecture at the Massachusetts Institute of Technology. Her work examines museums and exhibitions, and how the dissemination of visual culture is politically mediated by international organizations in the twentieth century.   Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/anthropology

How do you keep the cracks in Starry Night from spreading? How do you prevent artworks made of hugs or candies from disappearing? How do you render a fading photograph eternal—or should you attempt it at all? These are some of the questions that conservators, curators, registrars, and exhibition designers dealing with contemporary art face on a daily basis. In Still Life: Ecologies of the Modern Imagination at the Art Museum (University of Chicago Press, 2020), Fernando Domínguez Rubio delves into one of the most important museums of the world, the Museum of Modern Art (MoMA) in New York, to explore the day-to-day dilemmas that museum workers face when the immortal artworks that we see in the exhibition room reveal themselves to be slowly unfolding disasters. Still Life offers a fascinating and detailed ethnographic account of what it takes to prevent these disasters from happening. Going behind the scenes at MoMA, Domínguez Rubio provides a rare view of the vast technological apparatus—from climatic infrastructures and storage facilities, to conservation labs and machine rooms—and teams of workers—from conservators and engineers to guards and couriers—who fight to hold artworks still. As MoMA reopens after a massive expansion and rearranging of its space and collections, Still Life not only offers a much-needed account of the spaces, actors, and forms of labor traditionally left out of the main narratives of art, but it also offers a timely meditation on how far we, as a society, are willing to go to keep the things we value from disappearing into oblivion. This interview is part of an NBN special series on “Mobilities and Methods.” Fernando Domínguez Rubio is an Associate Professor at the Department of Communication at the University of California-San Diego. Alize Arıcan is a PhD candidate in the department of Anthropology at the University of Illinois at Chicago. Her work focuses on urban renewal, futurity, care, and migration in Istanbul, Turkey. Nushelle de Silva is a PhD candidate in the Department of Architecture at the Massachusetts Institute of Technology. Her work examines museums and exhibitions, and how the dissemination of visual culture is politically mediated by international organizations in the twentieth century.   Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/sociology

Title: Physician Suicide Target Audience This activity is directed to physicians who take care of hospitalized children, medical students, nurse practitioners, and physician assistants working in the emergency room, intensive care unit, or hospital wards. Objectives: Upon completion of this activity, participants should be able to: 1.      Review the epidemiology of Physician Suicide. 2.         Review the rates of physician suicide in comparison to general population. 3.         Review factors that are specific to increase the risk of physician suicide. Faculty:  Planning Committee: Allison Williams MD, — Assistant Professor of Pediatrics, Division of Pediatric Hospital Medicine, UPMC Children's Hospital of Pittsburgh Course Directors: Tony R. Tarchichi MD — Associate Professor, Department of Pediatrics, Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center (UPMC.) Paul C. Gaffney Division of Pediatric Hospital Medicine Dr. Tarchichi has disclosed he was a member of the Advisory Board for meningococcal vaccine in immunocompromised patient for Sanofi Corp Sidney Zisook MD - Professor, Department of Psychiatry, University of California San Diego. Conflict of Interest Disclosure: No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.   Accreditation Statement: In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.   The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.   Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.   Disclaimer Statement: The information presented at this activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine.  Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.   Released 12/19/2024,  Expires 12/19/2027   The direct link to the course is provided below:  

Can transforming thoughts and beliefs lead to measurable changes in your health and wellbeing?I'm thrilled to share this week's conversation with Dr Joe Dispenza. Dr Joe is a New York Times best-selling author, researcher, lecturer, and corporate consultant, known for his transformative teachings on the power of the mind to heal and shape reality. Since 2010, Dr Joe has partnered with renowned scientists and universities – including University of California San Diego, Harvard University, Stanford University, and others – to perform extensive research on the effects of meditation on the brain and body.Inspired by the latest findings in neuroscience, psychoneuroimmunology, epigenetics, and quantum physics, Dr Joe teaches people worldwide to rewire their brains, break free from limiting patterns, and unlock their potential – all of which (and more) is showcased in his most recent film, SOURCE - It's Within You.If you're curious about how to harness the mind's power to alter your experience and achieve greater fulfillment, this conversation is one you're going to want to listen deeply to. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

It's Tuesday, December 3rd, A.D. 2024. This is The Worldview in 5 Minutes heard on 125 radio stations and at www.TheWorldview.com.  I'm Adam McManus. (Adam@TheWorldview.com) By Kevin Swanson Chinese democracy activists get prison time The Chinese Communist government in Hong Kong has sentenced 45 democracy activists to prison time. The activists had participated in a political party for a primary not approved of by the state. At least two Christians, Benny Tai, age 60, and Joshua Wong, age 28, were among those sent to prison. Finnish officials cancel concert featuring Handel's Messiah A school in the former Christian-influenced nation of Finland cancelled a concert featuring segments of Handel's Messiah.  According to a news report from the Helsingin Salomat paper, the cancelled concert would have been a joint performance by the Finnish Baroque Orchestra and the Helsinki Chamber Choir. Biden-Harris Dept of Ed. persecuting Christian colleges The American Principles Project has released a report charging the Biden administration's Department of Education with persecuting Christian colleges. The report cites that nearly 70% of penalties imposed by the Department of Education's Office of Enforcement has been against Christian institutions and career colleges, even though these schools represent less than 10% of college students. And, within the last year, the Biden-Harris Department of Education imposed record fines against two of the nation's most prominent Christian universities.  It fined Grand Canyon University a whopping $37.7 million for allegedly “not fully informing” students about the costs of its doctoral programs on its website. University officials “categorically” denied the allegation. And the education bureaucrats levied a $14 million fine against Liberty University for alleged violations which stem from a failure to comply with crime-reporting requirements.  The Department's penalty, the largest ever for the category, hardly fits the accusation— especially considering steps the school voluntarily took to remedy its reporting and agreed to spend $2 million towards “on-campus safety improvements and compliance enhancements.” By comparison, Michigan State University was only fined $4.5 million in 2019 for failing to report sexual abuses by former team doctor Larry Nassar, who assaulted hundreds of victims The fines of the Christian colleges amount to more than all other penalties assessed by the Department of Education over the past seven years. Also, the report points out that funding for the heavy-handed enforcement has increased from $4 million to $61 million just since 2023. Planned Parenthood gave hearts of aborted babies to scientists Stomach-churning emails show Planned Parenthood negotiating terms regarding the donation of aborted fetuses for medical research, reports the New York Post. The emails discuss fetal tissue like any other commodity such as sugar or rice, nonchalantly negotiating for dead babies who were alive up to 23 weeks gestation from elective abortions. A heavily-redacted so-called “Research Plan” submitted to the University of California San Diego Institutional Review Board, and approved in 2018, states scientists wanted 2,500 dead babies from up to almost the sixth month of gestation for experimentation.  The plan gruesomely states, “We will collect tissues from fetuses ranging from 4 to 23 weeks gestational age from subjects undergoing elective surgical pregnancy termination at Planned Parenthood in San Diego.” Although selling fetal tissue is illegal, donating it is not illegal. The contract between University of California San Diego and Planned Parenthood appears to allow Planned Parenthood to retain “intellectual property rights” relating to the fetal tissue, although it also does not grant the school the independent right to “commercialize” the tissue.  David Daleiden, pro-life journalist and the founder of the Center for Medical Progress, obtained the emails by filing a California public records request. Let's remember the words of Psalm 94:2-3, 6-7, 8-10.  “Rise up, O Judge of the Earth; repay to the proud what they deserve! O Lord, how long shall the wicked exult? They kill the widow and the sojourner, and murder the fatherless; and they say, ‘The Lord does not see; the God of Jacob does not perceive.' “Understand, O dullest of the people. Fools, when will you be wise? He who planted the ear, does He not hear? He who formed the eye, does He not see? He who disciplines the nations, does He not rebuke?” Joe Biden pardons his son In a surprising turn around, President Joe Biden pardoned his son, Hunter Biden, of several firearms charges, and “all crimes committed between 2014 and 2024,” which could have added up to 17 years prison time, reports The Associated Press. Gun control has played a major part in the 4-year Biden administration. Between 1993 and 2008, while serving in the US Senate, Joe Biden voted against gun rights on all nine bills presented. Democrat Congresswoman Jasmine Crockett of Texas cheered him on. CROCKETT: “Way to go, Joe. Let me be the first one to congratulate the president for deciding to do this. Because, at the end of the day, we know that we have a 34-count convicted felon that is about to walk into the White House. So, for anyone that wants to clutch their pearls now, because he decided that he was going to pardon his son, I would say, take a look in the mirror.” But Scott Jennings, the conservative commentator on CNN, was aghast. JENNINGS: “This is the worst possible thing a president could possibly do to his party and to the country. To sit for a year and say, ‘I will not do this. The rule of law is sacred. We have to respect the justice system. We have to respect juries. We have to respect the guard rails and the norms of our democracy.' “These people are liars. Inflation: it's transitory. Afghanistan: it's a success. The border is secure. Robert Hur is a liar. The videos are cheap fakes. Biden has a cold. He'll never drop out. ‘Oh, I'll never pardon Hunter.' It's all a lie. It is all a grift. “Every American -- except the most partisan, brain-rotted people -- are going to be outraged by this today. He's disgraced. Joe Biden, [White House Press Secretary] Karine Jean-Pierre, how many minutes of tape do we have of both of these people telling the American people this will not happen? We could play it all morning. And it's a lie to benefit his own family. “He's drained every ounce of credibility from every surrogate. If Karine Jean-Pierre had an ounce of self-respect, she'd get off the plane in Africa today, where they're going so he can avoid the press, and resign. He's drained all of her credibility and everybody else who's defended this.” Interestingly, prior to the election, in an interview with Hugh Hewitt, President-elect Donald Trump said he would consider a pardon for Hunter Biden. Biden censors God in Thanksgiving Proclamation In other President Biden news, for the second year in a row, he issued a Thanksgiving proclamation completely avoiding any mention of God, reports Breitbart. Thus far, only Presidents Barack Obama and Joe Biden have left God out of Thanksgiving. Romans 1:21 explains that “although they knew God, they did not glorify Him as God, nor were thankful, but became futile in their thoughts, and their foolish hearts were darkened.” Homosexual couples adopt at 7x the rate as heterosexual couples And finally, courts are awarding homosexual male couples and  homosexual female couples living together in sin with adoptions at seven times the rate of heterosexual married couples, according to recent data from the Census Bureau.  A full 21% of homosexuals living in a sinful relationship have adopted children.  Tragically, the Mark Regnerus study conducted in 2012 found that 8% of children raised in homosexual homes are victims of incest.  Close And that's The Worldview on this Tuesday, December 3rd, in the year of our Lord 2024. Subscribe by Amazon Music or by iTunes or email to our unique Christian newscast at www.TheWorldview.com. Or get the Generations app through Google Play or The App Store. I'm Adam McManus (Adam@TheWorldview.com). Seize the day for Jesus Christ.

Could understanding the mystery of the Big Bang and how the Universe came into creation mean that we can finally know for sure if there is a creator? Professor Brian Keating is a cosmologist and experimental physicist at the University of California San Diego. He is the host of the ‘Into The Impossible' podcast and author of the books, ‘Losing The Nobel Prize' and ‘Into The Impossible: Think Like A Nobel Prize Winner'.  In this conversation, Brian and Steven discuss topics such as, how the discovery of the telescope changed the world, the link between our blood and the stars, the origins of the universe, and the scientific debate on God's existence.  (00:00) Intro (02:15) What Mission Are You On? (03:08) What Are Some Of The Most Controversial Questions You Set Out To Answer? (05:44) How Does God Tie Into The Creation Of The Universe Through A Scientific Lens? (08:26) $200 Million Project – Move Earlier (11:45) Meteor And 4-Billion-Year-Old Comet (15:38) Capturing The Origin Of The Universe (19:15) What Do You Suspect Is The Origin Of The Universe? (21:47) What Is The Most Compelling Evidence Of A God? (30:53) What Practices Help You Move Away From Being An Atheist? (39:09) Are We Searching For The Wrong Thing When It Comes To God? (41:30) If I Pray To This God, Will They Hear Me? (49:41) If It Was Proven God Wasn't Real, How Would Your Life Change? (53:48) What Is The Simulation Theory? (01:02:42) Do Aliens Exist? (01:17:45) What Is The Probability We're Alone? (01:24:31) Ads (01:25:31) Star Signs And Horoscopes (01:27:51) How Is Astrology Different From Religion? (01:30:07) What Is The Meaning Of Life? (01:32:43) What Was The Meaning Of Your Life Before Kids? (01:34:18) Do The Greats Feel Like Imposters? (01:40:13) The Importance Of Always Experimenting (01:41:09) Would You Ever Trade The Lack Of Privacy And Fame For Something Else? (01:43:25) The Last Guest's Question Follow Brian:  Instagram - https://bit.ly/4157xnt  Twitter - https://bit.ly/4eSKmjv  YouTube - https://bit.ly/4fQ9k4d  Podcast - https://bit.ly/3ZqRD5s  YouTube: You can purchase Brian's book, ‘Losing The Nobel Prize', here: https://amzn.to/4fOPR3M  Spotify: You can purchase Brian's book, ‘Losing The Nobel Prize', here: https://amzn.to/4fOPR3M  Watch the episodes on Youtube - https://g2ul0.app.link/DOACEpisodes  My new book! 'The 33 Laws Of Business & Life' is out now - https://g2ul0.app.link/DOACBook  You can purchase the The Diary Of A CEO Conversation Cards: Second Edition, here: https://g2ul0.app.link/f31dsUttKKb  Follow me: https://g2ul0.app.link/gnGqL4IsKKb Sponsors: Linkedin Jobs - https://www.linkedin.com/doac Learn more about your ad choices. Visit megaphone.fm/adchoices

I sat down with fellow Bay Area native, David Lim, one of the stars S.W.A.T. on CBS. He shares his personal experiences, career journey, and challenges he faced in the mortgage industry, acting, and modeling. We discussed the importance of resilience, self-belief, and adaptability in overcoming obstacles and achieving success in various fields. David shares the story of how he met his wife, and how they co-founded a jewelry company following a burglary of their home, losing sentimental pieces.  Bonus: My mom gets to ask her fan questions! S.W.A.T is on CBS every Friday at 8:00 pm and moving to 10:00 pm in the New Year To purchase Maya David jewelry: https://shopmayadavid.com/ Follow David on Instagram @davidbradleylim ========================================== Full bio:  David Lim is an Asian American actor, raised in San Ramon, California, and received a degree in Electrical Engineering from the University of California San Diego. He decided he wanted to do something different, signed a contract with Ford Models and moved to Los Angeles to pursue modeling and acting. He now stars as a series regular in the CBS drama S.W.A.T.

No właśnie, kiedy?Czy możemy uzależnić się od pornografii i czy interakcja z pornografią może wpływać na nasze seksualne życie?Po raz drugi mam przyjemność gościć prof. Mateusza Golę w podcaście, ale tym razem spotykamy się wokół uzależnienia od pornografii. A powodem tego spotkania jest jego nowa książka “Gdy porno przestaje być sexy. Pornografia oczami psychoterapeuta” wydana przez patrona dzisiejszego odcinka @copernicuscenterpress. Poza przeglądem badań, znajdziecie tam bardzo obrazowe case study, przykład pana X, pacjenta uzależnionego od pornografii. Idealny balans pomiędzy wnioskami z badań a doświadczeniem w pracy klinicznej. Gutral zdecydowanie poleca!Prof. dr hab. MATEUSZ GOLA – psycholog i neurokognitywista, pracownik naukowy Instytutu Psychologii Polskiej Akademii Nauk oraz University of California San Diego. Od 18 lat zajmuje się rozwijaniem wiedzy na temat neuronalnych mechanizmów uzależnień behawioralnych, opracowuje nowe metody terapii oraz pomaga osobom uzależnionym jako psychoterapeuta. Prowadzi stronę internetową www.mateuszgola.pl oraz kanał na YouTubie Mateusz Gola – Krótko i po ludzku.……………………………….

As we enter our teenage years, many of us feel like life is just getting started. But for dogs, celebrating a ‘teen' birthday is a sign of old age, entering a phase when things start slowing down. Listener Susan was besotted with her beloved corgi Copper John and wants to know why our furry companions rarely live as long as us. We investigate what accounts for the huge differences in lifespans across animal species. From fish that live a few weeks, to sharks who can survive for 500 years, what are the factors that affect the ticking on our biological clocks? Central to this field is the idea of ‘live fast, die young', with some animals burning more quickly through their ‘life fuel'. But is this rate set in stone?Presenter Anand Jagatia find out how animals' growth, reproduction and anti-ageing methods contribute to the length of their survival. Dr Kevin Healy, a macroecologist at the University of Galway, discusses some of these theories, explaining how the dangers and luxuries faced by animals during their evolution shape their speed of life. One example of extreme slow living is the Greenland Shark. John Fleng Steffensen, Professor of Marine Biology at the University of Copenhagen, describes how he helped figure out how old they really are, and how their cold living quarters increase their lifespan. Alessandro Cellerino, physiologist at the Scuola Normale Superiore in Pisa, finds the key to the sharks' longevity in their DNA.Anand also goes on a hunt on the west coast of Ireland for a creature that lives fast but surprisingly, dies old. Noel Fahy, research student at the University of Galway, is his guide, while Dr Nicole Foley, Associate Research Scientist at Texas A&M University, reveals the life-extending secrets of this creature.And geneticist Trey Ideker, Professor at the University of California San Diego, busts the myth that one dog year is seven human years. But how much is this misconception off by?Presenter: Anand Jagatia Producer: Julia Ravey Content Editor: Cathy Edwards Studio Manager: Sarah Hockley Production Coordinator: Ishmael Soriano(Photo: Copper John the Welsh Pembrokeshire Corgi, by listener Susan)

The NIEHS Superfund Research Program (SRP) is hosting a Risk e-Learning webinar series focused on using artificial intelligence (AI) and machine learning to advance environmental health research. The series will feature SRP-funded researchers, collaborators, and other subject-matter experts who aim to better understand and address environmental health issues by applying AI and machine learning approaches to complex issues. Recent advances in AI and machine learning methods show promise to improve the accuracy and efficiency of environmental health research. Over the course of three sessions, presenters will discuss how they use AI and machine learning approaches to improve chemical analysis, characterize chemical risk, understand microbial ecosystems, develop technologies for contaminant removal, and more. In the third and final session, ML & AI Applications to Understand Omics, Metabolomics, & Immunotoxicity and Optimize Bioengineering Using Datasets, Models, and Mass Spectrometry, speakers will discuss how they apply machine learning and artificial intelligence tools to analyze mass spectrometry and microscopy data and optimize models for understanding metabolomics, metabolite pathways, and immunotoxicology To learn about and register for the other sessions in this webinar series, please see the SRP website. Grace Peng, Ph.D., is a co-coordinator of the National Institutes of Health (NIH) Common Fund's Bridge to Artificial Intelligence (Bridge2AI) program, bridging the gap between the biomedical, behavioral and bioethics research communities and the data science/AI communities through a consortium of diverse experts to set the stage for widespread adoption of AI/ML in medicine. Dr. Peng will give an overview of the Bridge2AI program and introduce one of their projects at the University of California San Diego — Trey Ideker, Ph.D. Dr. Ideker will discuss the cell maps for AI (CM4AI) functional genomics project, one of four major data generation projects under the Bridge2AI program. The goal of the project is to provide a comprehensive map of human cellular components through generation of major spatial proteomics datasets. John Efromson, M.S., will present on Ramona Optic, Inc.'s Multi-Camera Array Microscope [MCAM(TM)], which is used to automate imaging and computer vision analysis of zebrafish and greatly improves previous throughput and analysis capabilities. Multiple applications of machine learning will be discussed, including behavioral pose estimation and phenotyping, morphological analysis, and cell counting and fluorescence quantification, as well as how these distinct analyses can be used together for pharmacology, toxicology, and neuroscience research. Speakers:Grace C.Y. Peng, Ph.D., Division of Discovery Science and Technology (Bioengineering), National Institute of Biomedical Imaging and Bioengineering and Trey Ideker, Ph.D., University of California San DiegoJohn Efromson, M.S., Ramona OpticsForest White, Ph.D., Massachusetts Institute of Technology (MIT)Moderator: Hunter Moseley, Ph.D., University of Kentucky To view this archive online or download the slides associated with this seminar, please visit http://www.clu-in.org/conf/tio/SRP-ML-AI3_112224/

The NIEHS Superfund Research Program (SRP) is hosting a Risk e-Learning webinar series focused on using artificial intelligence (AI) and machine learning to advance environmental health research. The series will feature SRP-funded researchers, collaborators, and other subject-matter experts who aim to better understand and address environmental health issues by applying AI and machine learning approaches to complex issues. Recent advances in AI and machine learning methods show promise to improve the accuracy and efficiency of environmental health research. Over the course of three sessions, presenters will discuss how they use AI and machine learning approaches to improve chemical analysis, characterize chemical risk, understand microbial ecosystems, develop technologies for contaminant removal, and more. In the third and final session, ML & AI Applications to Understand Omics, Metabolomics, & Immunotoxicity and Optimize Bioengineering Using Datasets, Models, and Mass Spectrometry, speakers will discuss how they apply machine learning and artificial intelligence tools to analyze mass spectrometry and microscopy data and optimize models for understanding metabolomics, metabolite pathways, and immunotoxicology To learn about and register for the other sessions in this webinar series, please see the SRP website. Grace Peng, Ph.D., is a co-coordinator of the National Institutes of Health (NIH) Common Fund's Bridge to Artificial Intelligence (Bridge2AI) program, bridging the gap between the biomedical, behavioral and bioethics research communities and the data science/AI communities through a consortium of diverse experts to set the stage for widespread adoption of AI/ML in medicine. Dr. Peng will give an overview of the Bridge2AI program and introduce one of their projects at the University of California San Diego — Trey Ideker, Ph.D. Dr. Ideker will discuss the cell maps for AI (CM4AI) functional genomics project, one of four major data generation projects under the Bridge2AI program. The goal of the project is to provide a comprehensive map of human cellular components through generation of major spatial proteomics datasets. John Efromson, M.S., will present on Ramona Optic, Inc.'s Multi-Camera Array Microscope [MCAM(TM)], which is used to automate imaging and computer vision analysis of zebrafish and greatly improves previous throughput and analysis capabilities. Multiple applications of machine learning will be discussed, including behavioral pose estimation and phenotyping, morphological analysis, and cell counting and fluorescence quantification, as well as how these distinct analyses can be used together for pharmacology, toxicology, and neuroscience research. Speakers:Grace C.Y. Peng, Ph.D., Division of Discovery Science and Technology (Bioengineering), National Institute of Biomedical Imaging and Bioengineering and Trey Ideker, Ph.D., University of California San DiegoJohn Efromson, M.S., Ramona OpticsForest White, Ph.D., Massachusetts Institute of Technology (MIT)Moderator: Hunter Moseley, Ph.D., University of Kentucky To view this archive online or download the slides associated with this seminar, please visit http://www.clu-in.org/conf/tio/SRP-ML-AI3_112224/

Listen in or watch as host David Mandell interviews Dr. Benjamin Ostrander, Chief Resident in Otolaryngology at the University of California San Diego. David begins with questions he asks all physician guests to the program—about their initial interest in becoming a physician and in their particular area. Ben explains his family background in engineering, his initial degrees in engineering and bio engineering and his gravitation to medical school and surgery. David and Ben then focus on the topic of innovation in general and specifically how medicine can learn from other industries—first discussing how the checklist concept came to medicine from aviation. Ben shares some of his research on the science and art of hospitality and how these concepts could translate into medicine. David and Ben then jump into a number of potential ways medicine could benefit from lessons learned in hospitality—from patient experience to environmental factors to employee satisfaction. Finally, Ben provides further resources for those interested in applying these concepts into their practice or hospital workplace. Learn more, including additional show notes, links, and more, by visiting physicianswealthpodcast.com. Click here to get your FREE copy of our latest book, Wealth Strategies for Today's Physician!

China is the world's largest energy consumer and carbon emitter, accounting for one-third of global CO2 emissions. One of its biggest sources of emissions is coal, which plays a central role in China's economy. At the same time, however, China is the world's leading supplier of renewable energy, largely due to significant government investments in green technologies, including solar manufacturing, batteries, and minerals. In September 2020, China's leader Xi Jinping announced the goal of achieving peak CO2 emissions before 2030 and carbon neutrality before 2060.” This ambitious pledge, if realized, will be an important step in global efforts to limit global warming.In the past few years, the increasingly competitive and fraught relationship between the United States and China has spilled into the climate domain, threatening the potential for both countries to work together to address climate change. That is the topic of a recent commentary co-authored by Margaret Pearson and Michael Davidson. The paper is titled, “Where are the US and China on addressing climate change?”, and it can be found on the Brookings Institution website. In this episode of China Global, host Bonnie Glaser speaks with one of the authors, Michael Davidson, who is an assistant professor at the School of Global Policy and Strategy and the Mechanical and Aerospace Engineering Department of the Jacobs School of Engineering at the University of California San Diego. Timestamps[01:57] China's Approach to Addressing Climate Change[04:26] Considerations Behind China's Climate Policy [07:37] Doubling Down on Coal Domestically[10:34] Evaluating China's Progress Toward Carbon Neutrality[14:42] Security and China's Climate Change Policy[19:13] China's International Climate Cooperation[22:45] US-China Working Group on Enhancing Climate Action [30:27] The Green Belt and Road Initiative

Christopher Bystroff is a professor of Biology and Computer Science at Rensselaer Polytechnic Institute in Troy NY. He runs a laboratory that studies protein structure and design, working towards targetable fluorescent biosensors and a contraceptive vaccine.  Chris teaches courses in protein structure, computational modeling of proteins, computational modeling of human population, bioinformatics and genetic engineering. In 2021 he published a paper predicting the near-term downturn of the global human population. Chris has a B.A. from Carleton College and a  PhD from University of California San Diego, both degrees in chemistry. He lives in Troy, New York, with his wife Maria. They have two adult children. The KunstlerCast theme music is the beautiful Two Rivers Waltz written and performed by Larry Unger Side-note: my website is still off-line and we are going to rebuild it here on Substack. The blogs and podcasts will continue here, and readers can always reach at: jhkunstler@mac.com

(Conversation recorded on August 6th, 2024)     The damaging effects of humanity's disconnected relationship to Earth's ecosystems are broad and deep. Yet, despite targeted efforts to address these issues and mitigate risks, our insatiable appetite for fossil hydrocarbons continues to grow at an alarming rate. What will it take to reframe our relationship with nature to move forward in a symbiotic, life-supporting path?  In this episode, Nate is joined by longtime colleagues Tom Murphy and D.J. White for an in-depth exploration of the mounting ecological crises driven by human behavior and unsustainable energy consumption. Together, they offer both scientific insights and personal reflections on trends such as the rapid decline in wild animal populations, the rise of microplastic pollution, the overwhelming scale of human-built mass, and many other facets of this unparalleled time in human history.  Why is it so difficult for society to recognize the scale of ecological destruction, and what needs to change to raise awareness? In what ways is academia struggling to provide the systems understanding we need to address the pressing environmental challenges of our time? How could recognizing our kinship with all living beings reshape our relationship with the planet?   About Tom Murphy: Tom Murphy is a Professor of Physics at the University of California San Diego and is the Associate Director of the Center for Astrophysics and Space Sciences. He is also the author of Energy and Human Ambitions on a Finite Planet, and continues to write regularly on the challenges associated with long-term human success through his blog Do The Math.    About DJ White: DJ White is a co-founder of Greenpeace International and founder of EarthTrust.  He has played a leading role in protecting dolphins, whales, sea turtles, and countless other marine animals, including successfully stopping a national dolphin drive kill, and breaking the deadlock in capping the Kuwait oil fires. He was the driving force behind the transition to more dolphin-friendly tuna as well as stopping widespread use of ocean drift nets in the 1980s.    Show Notes and More Watch this video episode on YouTube   ---   Support Institute for the Study of Energy and Our Future Join our Substack newsletter Join our Discord channel and connect with other listeners  

Inequality persists in pay and career advancement between male and female urologists. In this episode of the BackTable Urology Podcast, Dr. Suzette Sutherland hosts Dr. Yahir Santiago-Lastra from the University of California San Diego. They discuss the gender wage gap in medicine, particularly amongst urologists. --- This podcast is supported by: Photocure https://www.photocure.com/ --- SYNPOSIS Dr. Santiago, a Latina from Puerto Rico and a first-generation physician, highlights the latest data on pay, research funding, and professional advancement for women physicians. They debunk common myths, discuss the importance of transparency, and emphasize the need for inclusive work environments. The conversation also covers the economic phenomena underlying current discrepancies and the benefits of fostering diversity. This episode offers valuable insights for leaders on retaining and nurturing talent within their organizations. --- TIMESTAMPS 00:00 - Introduction 06:28 - Impact of Menopause and Women's Health 10:33 - Gender Gaps in Urology 31:52 - The Meritocracy Myth 35:56 - The Abrasiveness Trap and Gender Schema 40:04 - Navigating Work Personalities 47:54 - Leadership and Inclusivity in Organizations 51:30 - Tokenism vs. True Inclusion 56:58 - The Benefits of a Diverse Workforce --- RESOURCES Photocure https://www.photocure.com/

Dr Joe Dispenza - A New York Times best-selling author, researcher, lecturer, and corporate consultant, Dr Joe Dispenza has developed a practical formula to help people transform their lives. Dr Joe's mission unifies complex branches of science in an approachable way, focused on proven research, “Stories of Transformation” testimonials, and the scientific data behind spontaneous remissions. Inspired by the latest findings in neuroscience, psychoneuroimmunology, epigenetics, and quantum physics, his work integrates essential knowledge about the mind-body connection which teaches people how to heal various health conditions and make significant changes in their lives. Since 2010, he has partnered with renowned scientists and universities including University of California San Diego, Harvard University, Stanford University, and others to perform extensive research on the effects of meditation on the brain and body.

If nations are to meet their sustainable energy goals, experts argue that batteries will be a crucial part of the equation. Not only are batteries key for many technologies, they'll also be necessary to meet energy demands with a power grid that is mainly supplied by renewable energy sources like wind and solar. Without batteries, power from those sources can't be stored for use when the sun isn't shining or the wind isn't blowing.Right now, many technologies depend on lithium-ion batteries. While they certainly work well and have revolutionized mobile devices and electric vehicles, there are drawbacks. First, the lithium, cobalt, and nickel they require can only be found in some countries, and there have been accusations of unethical mining practices, including child labor. The mining and production processes also emit a large amount of CO2, and the batteries themselves can explode and cause fires, although these incidents are becoming less common.A promising, greener solution to our battery needs could be something called a solid-state battery. Lithium-ion batteries conduct electricity through a liquid electrolyte solution, while solid-state batteries do so with solid materials, such as ceramic, glass, and sulfides. This means they have lower risk of fires, charge faster, have higher voltages, and can be recycled. However, their development has taken longer than expected, due to cost, production hurdles, and lack of large-scale, real-world testing.Earlier this month, teams at the University of Chicago Pritzker School of Molecular Engineering and the University of California San Diego published a paper in Nature Energy demonstrating the world's first anode-free, sodium-based, solid-state battery architecture, which can charge quickly and last for several hundred cycles. Its main ingredient, sodium, is much more abundant than lithium, cobalt, and nickel, which could mean more affordable and environmentally friendly batteries in the future.Ira Flatow sits down with Dr. Y. Shirley Meng, a professor at the University of Chicago Pritzker School of Molecular Engineering and chief scientist for energy storage science at Argonne National Laboratory, to talk about the advancement, and when we could expect to see these unique batteries in our devices.Transcript for this segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.